Patents by Inventor Luca Gobbi

Luca Gobbi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compounds as monoacylglycerol lipase inhibitors
    Patent number: 12281124
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: April 22, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Charles Bell, Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Buelent Kocer, Carsten Kroll, Bernd Kuhn, Marius Daniel Rinaldo Lutz, Fionn O'Hara, Hans Richter, Martin Ritter, Didier Rombach, Martin Kuratli
  • Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
    Patent number: 12180196
    Abstract: The invention relates to a compound of formula (I) wherein A1 and R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: December 31, 2024
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz
  • NOVEL PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF CANNABINOID RECEPTOR 2
    Publication number: 20240383872
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2, X and R1—R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 21, 2024
    Inventors: Luca Gobbi, Uwe Grether, Julian Kretz, Simon M. Ametamey
  • RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND
    Publication number: 20240308974
    Abstract: The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.
    Type: Application
    Filed: May 21, 2024
    Publication date: September 19, 2024
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz, Dieter Muri, Ahmed Haider Wahauib
  • CYCLOHEPTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20240294543
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: April 4, 2024
    Publication date: September 5, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Martin GOEBEL, Maria-Clemencia HERNANDEZ, Andrés Miguel OLIVARES MORALES, Hasane RATNI, Michael REUTLINGER, Valerie RUNTZ-SCHMITT
  • NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20240287082
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R5 and X are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: March 20, 2024
    Publication date: August 29, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Steven Paul HANLON, Maria-Clemencia HERNANDEZ, Roland HUMM, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT
  • Pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
    Patent number: 12071420
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2, X and R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: August 27, 2024
    Assignees: HOFFMANN-LA ROCHE INC., ETH ZUERICH
    Inventors: Luca Gobbi, Uwe Grether, Julian Kretz, Simon M. Ametamey
  • Arylsulfonamide derivatives
    Patent number: 12065399
    Abstract: The present invention provides new arylsulfonamide compounds having the general formula (I) wherein L, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: August 20, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Luca Gobbi, Georg Jaeschke, Henner Knust, Lothar Lindemann, Fionn O'Hara, Jean-Marc Plancher
  • NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20240270744
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: February 14, 2024
    Publication date: August 15, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andrés Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT
  • NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20240190889
    Abstract: The invention provides heterocyclic compounds having the general formula (1), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: February 1, 2024
    Publication date: June 13, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andres Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT, Nicolas ZORN
  • Radiolabeled cannabinoid receptor 2 ligand
    Patent number: 11999710
    Abstract: The present invention relates to a compound of formula (I) wherein R1, R2, and R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a radiolabeled ligand.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: June 4, 2024
    Assignees: HOFFMANN-LA ROCHE INC., ETH ZUERICH
    Inventors: Simon M. Ametamey, Luca Gobbi, Uwe Grether, Julian Kretz, Dieter Muri, Ahmed Haider Wahauib
  • HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS
    Publication number: 20240150373
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 26, 2023
    Publication date: May 9, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH, Martin KURATLI
  • PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES
    Publication number: 20240025883
    Abstract: Compounds having the general formula I wherein R1, R2, R3, R4, X1 and X2 are as described herein, composition including the compounds and methods of using the compounds for treatment of GPR17-mediated diseases.
    Type: Application
    Filed: August 24, 2023
    Publication date: January 25, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Luca GOBBI, Wolfgang GUBA, Dmitry MAZUNIN, Emmanuel PINARD, Antonio RICCI
  • SUBSTITUTED BENZO[f][l ,2,4JTRIAZOL0[4,3-a][l ,4JDIAZEPINES AS GABA A GAMMA! POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20240002393
    Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 4, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Michael REUTLINGER, Valerie RUNTZ-SCHMITT, Jaclyn Ivy WAMSTEEKER CUSULIN, Nicolas ZORN
  • Heterocyclic compounds
    Patent number: 11814375
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: November 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
  • Heterocyclic compounds as monoacylglycerol lipase inhibitors
    Patent number: 11802133
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: October 31, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Charles Bell, Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Buelent Kocer, Carsten Kroll, Bernd Kuhn, Marius Daniel Rinaldo Lutz, Fionn O'Hara, Hans Richter, Martin Ritter, Didier Rombach, Martin Kuratli
  • Substituted benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepines as GABA A GAMMA1 positive allosteric modulators
    Patent number: 11739095
    Abstract: Compounds having the general formula (I) wherein R1, R2, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: August 29, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Giuseppe Cecere, Luca Gobbi, Maria-Clemencia Hernandez, Frédéric Knoflach, Andreas Koblet, Eoin Cornelius O'Connor, Andres Miguel Olivares Morales, Michael Reutlinger, Valerie Runtz-Schmitt, Jaclyn Ivy Wamsteeker Cusulin, Nicolas Zorn
  • Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
    Patent number: 11655243
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 23, 2023
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Kenneth Atz, Luca Gobbi, Uwe Grether, Wolfgang Guba, Julian Kretz
  • BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20230141603
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds for treatment of CNS disorders.
    Type: Application
    Filed: October 18, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT, Jaclyn WAMSTEEKER CUSULIN, Nicolas ZORN
  • NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM
    Publication number: 20230142171
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: October 4, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Roland HUMM, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT, Christian SCHNIDER